Another antiviral drug maker focused on treating Hepatitis C that's experiencing a solid run...


Another antiviral drug maker focused on treating Hepatitis C that's experiencing a solid run higher today is Idenix Pharmaceutical (IDIX +11.5%). On Saturday, the company announced positive study results for its clinical-stage hep C drug candidates – IDX719 and IDX184, and presented updated cardiovascular safety and antiviral activity data from phase IIb studies of IDX184. The results were presented at the Annual Meeting for the American Association for the Study of Liver Diseases in Boston.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs